IP Library Granted Patent US 10,434,126
Granted Patent B2
US 10,434,126 · App. 15/639,874 · Granted Oct 8, 2019

Microbiota restoration therapy (MRT), compositions and methods of manufacture

Inventors: Lee A. Jones (Fridley, MN); Courtney R. Jones (Fridley, MN); Edwin J. Hlavka (Minneapolis, MN); Ryan D. Gordon (Edina, MN)
Assignee: REBIOTIX, INC.
A61K35/74A61K9/0031A61K9/0053A61K35/38A61K47/10A61K9/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,126
App. No.
15/639,874
Granted
Oct 8, 2019
Kind
B2
Abstract

Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method may include a method of treating an infection. The method may comprise administering a microbiota restoration therapy composition to a patient with an infection. The microbiota restoration therapy composition may comprise a mixture of an effective amount of fecal microbiota and an effective amount of polyethylene glycol.

Claims (28)

1. A method of treating an infection, the method comprising:

administering an antibiotic to a patient having an infection;

wherein the infection includes a vancomycin-resistant enterococci infection or a methicillin-resistant Staphylococcus aureus infection; and

after administering the antibiotic, administering a dose of a microbiota restoration therapy composition to the patient;

wherein the microbiota restoration therapy composition comprises a mixture of an effective amount of fecal microbiota from a fresh human fecal sample and polyethylene glycol at a concentration of 30-90 g/L.

2. The method of claim 1 , wherein the antibiotic includes vancomycin, fidaxomicin, rifaximimin, linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole, televancin, teicoplanin, dalbavancin, metronidazole, ortivancin, or a combination thereof.

3. The method of claim 1 , further comprising after administering the dose of microbiota restoration therapy, administering a secondary dose of a microbiota restoration therapy composition.

4. The method of claim 1 , wherein administering the antibiotic comprises administering a primary antibiotic followed by a secondary antibiotic.

5. The method of claim 1 , further comprising after administering the dose of the microbiota restoration therapy composition, administering a secondary antibiotic.

6. The method of claim 1 , wherein administering a dose of a microbiota restoration therapy composition to the patient includes administering the microbiota restoration therapy composition with an enema tube.

7. The method of claim 1 , wherein administering a dose of a microbiota restoration therapy composition to the patient includes orally administering the microbiota restoration therapy composition.

8. A method of treating a drug resistant infection, the method comprising:

administering a primary antibiotic to a patient having an infection;

wherein the infection includes a vancomycin-resistant enterococci infection or a methicillin-resistant Staphylococcus aureus infection;

administering a secondary antibiotic to the patient with the infection;

after administering the primary and secondary antibiotics, administering a primary dose of a microbiota restoration therapy composition to the patient with the infection; and

wherein the microbiota restoration therapy composition comprises a mixture of an effective amount of fecal microbiota from a fresh human fecal sample and polyethylene glycol at a concentration of 30-90 g/L and is pre-screened for bacterial diversity.

9. The method of claim 8 , further comprising administering a secondary dose of a microbiota restoration therapy composition to the patient with the infection.

10. The method of claim 8 , further comprising administering a post-treatment antibiotic to the patient after administering the primary microbiota restoration therapy composition to the patient.

11. The method of claim 10 , wherein the primary antibiotic, secondary antibiotic, and/or post-treatment antibiotic includes vancomycin, fidaxomicin, rifaximimin, linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole, televancin, teicoplanin, dalbavancin, metronidazole, ortivancin, or a combination thereof.

12. A method of treating a drug resistant infection, the method comprising:

administering a primary antibiotic to a patient having a drug resistant infection;

wherein the infection includes a vancomycin-resistant enterococci infection or a methicillin-resistant Staphylococcus aureus infection;

after administering the primary antibiotic, administering a primary dose of a microbiota restoration therapy composition to the patient with the infection;

administering a secondary dose of a microbiota restoration therapy composition to the patient; and

wherein the primary and/or secondary doses of microbiota restoration therapy composition comprises a mixture of an effective amount of fecal microbiota from a fresh human fecal sample and polyethylene glycol at a concentration of 30-90 g/L and is pre-screened for bacterial diversity.

13. The method of claim 12 , wherein administering a primary dose and/or a secondary dose of a microbiota restoration therapy composition to the patient includes administering the microbiota restoration therapy composition with an enema tube.

14. The method of claim 12 , wherein administering a primary dose and/or a secondary dose of a microbiota restoration therapy composition to the patient includes orally administering the microbiota restoration therapy composition.

Assignments (1)
CHANGE OF NAME Recorded Jan 27, 2025
From: REBIOTIX INC.
To: FERRING MICROBIOME INC.
Reel/Frame 070022/0505 →
Continuity (6)
Continuation 15341303 · Nov 2, 2016
Continuation 14529522 · Oct 31, 2014
Continuation In Part 14504927 · Oct 2, 2014
Continuation In Part 14295686 · Jun 4, 2014
Provisional Application 61831409 · Jun 5, 2013
Related Publication 20170296597A1 · Oct 19, 2017
Cited By (1)
US 12,303,537